Skip Navigation LinksHome > April 20, 2014 - Volume 39 - Issue 9 > Prospective, Randomized, Controlled Trial of Silicate-Substi...
Text sizing:
A
A
A
Spine:
doi: 10.1097/01.brs.0000446519.14737.28
Erratum

Prospective, Randomized, Controlled Trial of Silicate-Substituted Calcium Phosphate Versus rhBMP-2 in a Minimally Invasive Transforaminal Lumbar Interbody Fusion: Erratum

Free Access

The article that appeared on page 185 in the February 1, 2014 issue included a footnote section which incorrectly stated the following:

The device(s)/drug(s) that is/are the subject of this manuscript is/are being evaluated as part of an ongoing FDA-approved investigational protocol (IDE) or corresponding national protocol.

However, the correct statement should be:

The device(s)/drug(s) that is/are the subject of this manuscript is/are not FDA-approved for this indication and is/are not commercially available in the United States. Actifuse was utilized in an on-label fashion whereas rhBMP-2 is considered “off-label” use in the setting of transforaminal lumbar interbody fusion. This was an independent study.

Back to Top | Article Outline

Reference

1. Nandyala SV, Marquez-Lara A, Fineberg SJ, Pelton M, Singh K. Prospective, randomized, controlled trial of silicate-substituted calcium phosphate versus rhBMP-2 in a minimally invasive transforaminal lumbar interbody fusion. Spine 2014;39:185–191.

© 2014 by Lippincott Williams & Wilkins

Follow Us!

  

Login